Introduction:
Aurigene Pharmaceutical Services is set to open a new biologics facility in India, providing process development and clinical-scale manufacturing capabilities.
Features:
This state-of-the-art facility boasts top-tier equipment and control systems, supported by a highly skilled talent pool, ensuring a seamless transition to large-scale commercial CGMP manufacturing facilities. Additionally, it will efficiently aid in the development of innovative medicines.
The facility is designed to support process and analytical development needs, as well as small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical trials.
Complementing the existing discovery capabilities and infrastructure, which mainly focuses on recombinant proteins such as monoclonal antibodies, bispecific and multispecific antibodies, immune-fusion molecules, antibody-drug conjugates, and other complex proteins.
This new facility in Genome Valley will deliver robust, compliant, and economically viable cell lines, process development solutions, and supporting analytical methods to facilitate rapid entry and progression through clinical development stages.
The process and analytical development laboratories are now operational, with the manufacturing capacity set to be commissioned by the end of 2024.
Specifications:
Name Aurigene Pharmaceutical Services
Type New Construction
Year 2024
